

Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

NCT07370766

Status RECRUITING
Sponsor Chronicle Academy
Enrollment 80 participants

Key Eligibility Criteria

Inclusion (8)

- Adults aged 18 years or older.
- Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA \geq 3%).
- Candidate for phototherapy and/or systemic therapy.
- Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose.
- a. Decision to treat with tildrakizumab must be made independently of and prior to study recruitment.

... and 3 more (see full listing online)

Exclusion (8)

- Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph.
- Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin)
- Diagnosis of only palmoplantar psoriasis
- Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments
- Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding.

... and 3 more (see full listing online)

Locations (6 total)

Burlington Skin and Wellness, Burlington, Ontario, Canada
Locke Dermatology, Hamilton, Ontario, Canada
Panorama Dermatology Clinic, Kanata, Ontario, Canada
... and 3 more locations